Azura Ophthalmics Ltd.

Notal Vision Inc.

M.g. Therapeutics, Ltd.

Pres-by Vision Ltd.

Reichert, Inc.

Nexisvision, Inc.

Omer Rafaeli

Hanson S Gifford, Iii

Yair Alster

Doron Friedman

Shimon Amselem

Cary J Reich

Amit Pascal

Charles Bosworth

Gidon Goren-Gratzyani

Kirsten Angela Macfarlane

K Angela Macfarlane

Jonathan Dunn

Robert M Burk

Eugene De Juan, Jr

Douglas Sutton

Jose D Alejandro

John Anthony Scholl

Marc Gleeson

Mark Richard Stewart

Ian Holmes

Hila Barash

Zakhar Nudelman

Hila Epstein-Barash

Hanoch Gideon Benyamini

Matt Clarke

Eitan Sharif

Barak Azmon

Nicholas Chapman

Muki Rapp

Ofer Pintel

Edward Elikhis

Kester Nahen

Moshe Havilio

Yael Alon

Elad Bergman

Alexander James Nicholls

Cary Reich

Systems and relative method of monitoring the state of a subject's retinal disease employ remote based OCT imaging of a subject's retina. A method includes receiving optical coherence tomography (OCT) image data of a retina of a subject for each of a series of OCT imaging sessions of the retina. The OCT image data of the retina is processed to determine a series of measured extent values. Each of the one or more measured extent values is indicative of a respective extent of the retinal disease.

OCT guided therapy

Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said methods are performed by administering said composition comprising a selenium disulfide and an anhydrous semi-solid base. The stable anhydrous composition are substantially free of selenium disulfide agglomerates.

Selenium disulfide compositions for use in treating meibomian gland dysfunction

Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.

Compositions and methods for the treatment of meibomian gland dysfunction

Ophthalmic imaging devices and related methods employ self-alignment of a user with an optical axis of the imaging device. An ophthalmic imaging device includes a retinal imaging assembly, a housing assembly, and a viewer assembly. The retinal imaging assembly has an optical axis. The retinal imaging assembly is attached to the housing. The housing assembly is configured to rest on a horizontal surface during operation of the retinal imaging assembly. The optical axis is oriented at an angle from the horizontal surface when the housing assembly rests on the horizontal surface. The viewer assembly is coupled with the housing assembly. The viewer assembly includes an interface surface shaped for engagement with each head of a plurality of different user's and to accommodate repositioning of the head to align a pupil of the user with the optical axis.

Retinal imaging device and related methods

Described herein are compositions and methods for the treatment of contact lens discomfort (CLD) and/or lid wiper epitheliopathy (LWE). Such compositions comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of such compositions to the inner surface of the eyelid provides therapeutic benefit to patients suffering from contact lens discomfort (CLD) and/or lid wiper epitheliopathy (LWE).

Compositions and methods for the treatment of contact lens discomfort

Retinal imaging systems and related methods employ a user specific approach for controlling the reference arm length in an optical coherence tomography (OCT) imaging device. A method includes generating a signal indicative of a position of a feature of a user's head relative to an OCT imaging device. A user specific reference arm adjustment length range for the user within a reference arm adjustment length range of the OCT device is determined based on the signal. A reference arm length adjustment module is controlled during an imaging of the retina to vary a reference arm length of the OCT imaging device within the user specific reference arm adjustment length range to identify an imaging reference arm length for which an OCT image detector of the OCT imaging device produces an OCT signal corresponding to the retina of the user.

Automatic optical path adjustment in home OCT

Dynamic contact lenses fabricated with a dynamic portion that extends outward from the peripheral portion are disclosed. When worn on an eye the dynamic portion forms a tear lens for correcting vision. The dynamic portion can also be configured to provide a dynamic tear lens that changes optical power with forces applied by eyelids. The dynamic portion can be configured to assume a conforming configuration and at least one non-conforming configuration, or can be configured to assume at least two non-conforming configurations. The dynamic contact lenses can be used for correcting vision such as correcting presbyopia.

Dynamic tear lenses

Ophthalmic imaging systems and related methods provide pseudo feedback to aid a user in aligning the user's eye with an optical axis of the imaging system. An ophthalmic imaging system includes an ophthalmic imaging device having an optical axis, a display device, an eye camera, and a control unit. The display device displays a fixation target viewable by the user. The eye camera images the eye to generate eye image data. The control unit processes the eye image data to determine a position of the eye relative to the optical axis, processes the position of the eye relative to the optical axis to generate a pseudo position of the eye relative to the optical axis, and causes the display device to display an indication that provides feedback to the user that the eye is located at the pseudo position of the eye relative to the optical axis.

Methods and systems for alignment of ophthalmic imaging devices

Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory/infections disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugate which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eye, ocular surface or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

Compounds and methods for the treatment of ocular disorders

Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

Provided herein are methods treating a disease or disorder in or around the eye with a pharmaceutical composition comprising selenium disulfide (SeS) and instructing the treated individual to limit or avoid exposure to light following administration in order to reduce the adverse effect of the composition.

Instructions for composition and sensitivity

Growing community of inventors

Udim, Israel

Omer Rafaeli